Can collagen type II sustain a methotrexate-induced therapeutic effect in patients with long-standing rheumatoid arthritis? A double-blind, randomized trial

British Journal of Rheumatology

Volumn 37, Issue 10, 1998, Pages 1110-1117

  Hauselmann H J ^a   Caravatti, M ^a   Seifert, B ^b   Wang, K ^b   Bruckner, P ^c   Stucki, G ^a   Michel, B A ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Clinical trial; Collagen type II; Comparative study; Methotrexate; Oral immune tolerance; Rheumatoid arthritis

Indexed keywords

COLLAGEN TYPE 2; CORTICOSTEROID; METHOTREXATE; PLACEBO;

ADULT; ALOPECIA; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; FEMALE; HEARTBURN; HUMAN; IMMUNOLOGICAL TOLERANCE; MAJOR CLINICAL STUDY; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN STRUCTURE; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SIDE EFFECT; STOMACH PAIN; TREATMENT FAILURE;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COLLAGEN; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNE TOLERANCE; JOINTS; MALE; METHOTREXATE; MIDDLE AGED; MOUTH MUCOSA; TREATMENT OUTCOME;

EID: 0031782931     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Wolfe F, Hawley DJ, Cathey MA. Termination of a slow acting antirheumatic therapy in RA: a 14 year prospective evaluation of 1017 consecutive starts. J Rheumatol 1990;17:994-1002.
2. Alarcon GS, Tracy IC, Strand GM, Singh K, Macaluso M. Survival and drug discontinuation analysis in a large cohort of methotrexate treated rheumatoid arthritis patients. Ann Rheum Dis 1995;54:708-12.
3. Weiner HL, Friedman A, Miller A, Khoury SJ, al-Sabbagh A, Santos L et al. Oral tolerance: immunologic mechanism and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu Rev Immunol 1994; 12:809-37.
4. Miller A, Hafler DA, Weiner HL. Tolerance and suppressor mechanisms in experimental autoimmune encephalomyelitis; implications for immunotherapy of human autoimmune diseases. FASEB J 1991;5:2560-6.
5. Nagler-Anderson C, Bober LA, Robinson ME, Siskind GW, Thorbecke GJ. Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen. Proc Natl Acad Sci USA 1986; 83:7443-6.
6. Myers LK, Stuart JM, Seyer JM, Kang AH. Identification of an immunosuppressive epitope of type II collagen that confers protection against collagen-induced arthritis. J Exp Med 1989;170:1999-2010.
7. Zhang ZY, Lee CSY, Lider O, Weiner HL. Suppression of adjuvant arthritis in Lewis rats by oral administration of type II collagen. J Immunol 1990;145:2489-93.
8. Miller EJ. Biochemical characteristics and biological significance of the genetically distinct collagens. Mol Cell Biochem 1976;13:165-92.
9. Miller A, Lider O, Weiner HL. Antigen-driven bystander suppression after oral administration of antigens. J Exp Med 1991;174:791-8.
10. Trentham DE, Dynesius-Trentham RA, Orav EJ, Combitchi D, Lorenzo C, Sewell KL et al. Effects of oral administration of type II collagen on RA. Science 1993;261:1727-30.
11. Sieper J, Kary S, Sörensen H, Alten R, Eggens U, Hüge W et al. Oral type II collagen treatment in early RA: A double-blind, placebo-controlled, randomized trial. Arthritis Rheum 1996;39:41-51.
12. Arnett FC, Edworthy SM, Bloch DA, Mcshane DJ, Fries JF, Cooper NS et al. The American Rheumatism Association 1987 revised criteria for the classification of RA. Arthritis Rheum 1988;31:315-24.
13. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in RA. Arthritis Rheum 1992; 35:498-502.
14. Kastenbaum MA, Hoel DG, Bowman KO. Sample size requirements: one-way analysis of variance. Biometrika 1970;57:421-30.
15. Reese CA, Mayne R. Minor collagens of chicken hyaline cartilage. Biochemistry 1981;20:5443-8.
16. Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 h: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992;39:225-35.
17. Blasczyk R, van Lessen A, Schwella N, Huhn D, Salama A. A novel HLA DR 13 allele (DRB1*1314) identified by single-strand conformation polymorphism analysis and confirmed by direct sequencing. Hum Immunol 1995;43:303-12.
18. Ollier W, Thomson W. Population genetics of RA. Rheum Dis Clin North Am 1992;18:741-59.
19. Weyand CM, Hicok KC, Conn DL, Goronzy JJ. The influence of HLA-DRB1 genes on disease severity in RA. Ann Intern Med 1992;117:801-6.
20. Fuchs HA, Brooks RH, Callahan LF, Pincus T. A simplified twenty-eight-joint quantitative articular index in RA. Arthritis Rheum 1989;32:531-7.
21. Van der Heijde DMFM, van't Hof MA, van Riel PLCM, van Leeuwen MA, van Rijswijk MH, van de Putte LBA. Validity of single variables and composite indices for measuring disease activity in RA. Ann Rheum Dis 1992;51:177-81.
22. Scott DL, van Riel PLCM, van der Heijde DMFM, Benke AS. Assessing disease activity in RA. The EULAR handbook of standard methods, 1994.
23. Prevoo MLL, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LBA, van Riel PLCM. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with RA. Arthritis Rheum 1995;38:44-8.
24. Van Gestel AM, Prevoo MLL, van't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for RA. Arthritis Rheum 1996;39:34-40.
25. Mason JH, Anderson JJ, Meenan RF, Haralson KM, Lewis-Stevens D, Kaine JL. The rapid assessment of disease activity in rheumatology (RADAR) questionnaire: validity and sensitivity to change of a patient self-report measure of joint count and clinical status. Arthritis Rheum 1992;35:156-62.
26. Mason JH, Meenan RF, Anderson JJ. Do self-reported arthritis symptom (RADAR) and health status (AIMS2) data provide duplicative or complementary information? Arthritis Care Res 1992;5:163-72.
27. Stucki G, Liang MH, Stucki S, Brühlmann P, Michel BA. A self-administered RA disease activity index (RADAI) for epidemiologic research: Psychometric properties and correlation with parameters of disease activity. Arthritis Rheum 1995;38:795-8.
28. Stucki G, Schönbächler J, Brühlmann P, Mariacher S, Stoll T, Michel BA. Does a muscle strength index provide complementary information to traditional disease activity variables in patients with RA? J Rheumatol 1994;21:2200-5.
29. Fries JF, Spitz PW, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
30. Brühlmann P, Stucki G, Michel BA. Evaluation of a German version of the physical dimension of the health assessment questionnaire in patients with RA. J Rheumatol 1994;21:1245-9.
31. Ramey DR, Raynaud JP, Fries J. The health assessment questionnaire 1992. Status and review. Arthritis Care Res 1992;5:9-29.
32. Ware JE, Sherbourne CD. The MOS 36-item short form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
33. Ware JE. SF-36 health survey. Manual and interpretation guide. Boston: The Health Institute, New England Medical Center, 1993.
34. McHorney CA, Ware JE, Lu JFR, Sherbourne CD. The MOS 36-item short-form health survey (SF-36) III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994;32: 40-63.
35. Barnet ML, Kremer JM, St Clair EW, Clegg DO, Furst D, Weisman M et al. Treatment of rheumatoid arthritis with oral type II collagen. Arthritis Rheum 1998; 41:290-7.